Skip to main content

Year: 2024

Verisk Reports Third-Quarter 2024 Financial Results

Consolidated revenues were $725 million, up 7.0%, and up 6.8% on an organic constant currency (OCC) basis for the third quarter of 2024. Income from continuing operations was $220 million, up 17.4% for the third quarter of 2024. Adjusted EBITDA, a non-GAAP measure, was $401 million, up 9.4%, and up 7.2% on an OCC basis.  Diluted GAAP earnings per share from continuing operations (diluted EPS) were $1.54 for the third quarter of 2024, up 19.4%. Diluted adjusted earnings per share (diluted adjusted EPS), a non-GAAP measure, were $1.67, up 9.9%. Net cash provided by operating activities was $296 million, up 18.4% and free cash flow, a non-GAAP measure, was $241 million, up 22.9% for the third quarter of 2024.  We paid a cash dividend of 39 cents per share on September 30, 2024, and repurchased $400 million of our common shares during the...

Continue reading

Lifeist Reports Third Quarter 2024 Financial Results

TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B0) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness,  today reported its financial results for the three months ended August 31, 2024 (“Q3 2024”) compared to the same period last year (“Q3 2023”). All financial figures are in Canadian dollars unless otherwise indicated. Third Quarter HighlightsNet revenue from continued operations of $2.1 million in Q3 2024 compared to $4.8 million in Q3 2023. Gross profit before inventory adjustment of $0.9 million in Q3 2024, representing gross margin of 43%, compared to $3.1 million, or 65% gross margin, in Q3 2023. Total expenses decreased $1.4 million to $1.8 million...

Continue reading

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – – $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2024,...

Continue reading

Canoo Partners with The AA in the UK for Premium Roadside Assistance Services to Commercial and Government Customers

JUSTIN, Texas and LONDON, Oct. 30, 2024 (GLOBE NEWSWIRE) — Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced that the company has signed an agreement with The AA, the UK’s No.1 breakdown provider, to enhance the customer experience with premium service and repair for Canoo’s commercial fleet and government customers throughout the United Kingdom. The AA (Automobile Association) has a rich history in the UK, having been established almost 120 years ago. It has evolved from its origins in providing roadside assistance to becoming a significant player in managing a vast fleet of vehicles for businesses. With a breakdown customer base of over 11 million business vehicles, the AA offers a comprehensive range of services tailored to various vehicle types, including cars, vans, and trucks both under and...

Continue reading

Tecnoglass Named to Fortune’s 100 Fastest-Growing Companies List

– Only Company in the Materials Segment Recognized on the List – – Based on Revenue and Adjusted EPS Growth of 65% and Over 200%, Respectively, From 2021 to LTM June 2024 – Miami, FL, Oct. 30, 2024 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced it has been ranked by Fortune Magazine as the 27th fastest-growing company in the United States for 2024. The prestigious recognition is based on Tecnoglass’ strong revenue growth, earnings per share growth, and three-year annualized return to shareholders for the period ended June 30, 2024. José Manuel Daes, Chief Executive Officer of Tecnoglass, commented,...

Continue reading

GXO’s State-of-the-art Dormagen Site at Full Capacity

Dormagen Site PR interiorGXO continues its multi-year plan to significantly expand its operations in Germany, Europe’s largest logistics marketIndustry leader continues its multi-year plan to significantly expand its operations in Germany, Europe’s largest logistics market Customers include prominent industry leaders in aerospace, food & beverage and consumer goodsDORMAGEN, Germany, Oct. 30, 2024 (GLOBE NEWSWIRE) — GXO Logistics, Inc. (NYSE: GXO), the world’s largest pure-play contract logistics provider, today announced its state-of-the-art 36,000 square meter multi-tenant warehouse in Dormagen near Düsseldorf is completely at full capacity an important milestone in the US company’s growth strategy in Germany. “We see a long runway for growth in the German contract logistics market where demand for increased...

Continue reading

Dragonfly Energy to Report Third Quarter 2024 Financial and Operational Results on November 14, 2024

RENO, Nev., Oct. 30, 2024 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), maker of Battle Born Batteries® and an industry leader in energy storage, today announced that the Company will release its financial and operational results for the third quarter ended September 30, 2024 after market close on Thursday, November 14, 2024. The earnings press release will be followed by a conference call on November 14, 2024 at 5:00 PM Eastern Time. Interested investors and other parties may access the live webcast via the link found here or through the Events and Presentations page within the Investor Relations section of Dragonfly Energy’s website at https://investors.dragonflyenergy.com/events-and-presentations/default.aspx. The call can also be accessed live via telephone by dialing...

Continue reading

Banco Santander-Chile Announces Third Quarter 2024 Earnings

SANTIAGO, Chile, Oct. 30, 2024 (GLOBE NEWSWIRE) — Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its results1 for the nine-month period ended September 30, 2024, and third quarter 2024 (3Q24). ROAE2 of 23.1% in 3Q243 and 18.2% in 9M244. In the third quarter of 2024 (3Q24), the Bank’s net income attributable to shareholders totaled $243,133 million ($1.29 per share and US$ 0.58 per ADR), reflecting an increase of 11.7% compared to the previous quarter (2Q24), with an ROAE of 23.1%. As of September 30, 2024, the Bank’s net income attributable to shareholders totaled $581.109 billion ($3.08 per share and US$1.37 per ADR), reflecting an increase of 81.9% compared to the same period of the previous year and with an ROAE of 18.2%. The increase in results in the quarter is explained by an increase in the...

Continue reading

Kirby Corporation Announces 2024 Third Quarter Results

Third quarter 2024 earnings per share of $1.55 Continued strength in inland marine with a sequential increase in spot market prices and operating margins in the low 20% range Continued strong market conditions in coastal marine with operating margins improving to the mid-teens range Strong free cash flow generation with over $130 million of free cash flow in the third quarter Kirby repurchased 483,335 shares at an average price of $115.46 for $55.8 million in the 2024 third quarterHOUSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) — Kirby Corporation (“Kirby”) (NYSE: KEX) today announced net earnings attributable to Kirby for the third quarter ended September 30, 2024, of $90.0 million or $1.55 per share, compared with earnings of $63.0 million, or $1.05 per share for the 2023 third quarter. Consolidated revenues for the 2024 third quarter...

Continue reading

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich’s ataxia (FA) receiving 25 mg of nomlabofusp daily for 30-180 days in ongoing open label extension (OLE) study Initiation of PK run-in study in adolescents on track by year-end 2024 Initiation of global confirmatory/registration study planned mid-2025 Biologics License Application (BLA) submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval Strong balance sheet of $203.7 million cash, cash equivalents and marketable securities as of September 30, 2024, with projected cash runway into 2026BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) — October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq:...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.